NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP
Mesoblast Limited MESO
10 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
$17.2M
▲ 191.4% vs FY2023
EPS · FY24
$-0.08
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
—
Net margin · FY24
-593.9%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 17.2M
Revenue, FY2024 · full 10-year series below
Revenue
Net income
The company lost 594 cents on every revenue dollar this year.
Per share
USD -0.08
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2024
ROE
Operating margin—
Net margin-593.9%
Return on assets-14.1%
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−11.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+19.0%
−11.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 784.7M
total assets, end of FY2024
Total assetsUSD 784.7M
CashUSD 161.6M
Gross debtUSD 121.9M
Net debtUSD -39.7M
Current ratio1.99×
History
10 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
·
·
·
·
·
·
·
·
·
·
EBITDA $B
·
·
·
·
·
·
·
·
·
·
Income tax $B
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
Net income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.1
−0.0
EPS, diluted $
−0.08
−0.09
−0.11
−0.13
−0.16
−0.15
−0.18
−0.08
−0.19
−0.01
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
·
·
·
Shares out B
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
28 of 28
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed